RxSight (RXST) Competitors

$7.26 -0.12 (-1.63%)

Closing price 04:00 PM Eastern

Extended Trading

$7.27 +0.01 (+0.14%)

As of 04:56 PM Eastern

RXST vs. AVNS, IRMD, CNMD, BLFS, and INMD

Should you be buying RxSight stock or one of its competitors? The main competitors of RxSight include Avanos Medical (AVNS), iRadimed (IRMD), CONMED (CNMD), BioLife Solutions (BLFS), and InMode (INMD). These companies are all part of the "medical equipment" industry.

How does RxSight compare to Avanos Medical?

RxSight (NASDAQ:RXST) and Avanos Medical (NYSE:AVNS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

: Avanos Medical has a net margin of -10.40% compared to RxSight's net margin of -28.96%. Avanos Medical's return on equity of 5.47% beat RxSight's return on equity.
Company Net Margins Return on Equity Return on Assets
RxSight -28.96% -14.05% -12.54%
Avanos Medical -10.40% 5.47% 4.05%
: RxSight has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500.
: 78.8% of RxSight shares are held by institutional investors. Comparatively, 95.2% of Avanos Medical shares are held by institutional investors. 9.6% of RxSight shares are held by company insiders. Comparatively, 2.3% of Avanos Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: RxSight has higher earnings, but lower revenue than Avanos Medical. Avanos Medical is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RxSight $134.48M 2.24 -$38.94M -$0.95 N/A
Avanos Medical $701.20M 1.64 -$72.90M -$1.58 N/A
: RxSight currently has a consensus target price of $9.78, indicating a potential upside of 34.68%. Given RxSight's stronger consensus rating and higher probable upside, research analysts plainly believe RxSight is more favorable than Avanos Medical.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RxSight
3 Sell rating(s)
10 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
1.93
Avanos Medical
1 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.50
: In the previous week, Avanos Medical had 3 more articles in the media than RxSight. MarketBeat recorded 6 mentions for Avanos Medical and 3 mentions for RxSight. Avanos Medical's average media sentiment score of 0.44 beat RxSight's score of 0.00 indicating that Avanos Medical is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
RxSight
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Avanos Medical
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-28.96%	-14.05%	-12.54%
Avanos Medical	-10.40%	5.47%	4.05%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	2.24	-$38.94M	-$0.95	N/A
Avanos Medical	$701.20M	1.64	-$72.90M	-$1.58	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
Avanos Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Avanos Medical	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

RxSight and Avanos Medical tied by winning 8 of the 16 factors compared between the two stocks.

How does RxSight compare to iRadimed?

iRadimed (NASDAQ:IRMD) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

: iRadimed has higher earnings, but lower revenue than RxSight. RxSight is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
iRadimed $86.28M 12.72 $22.48M $1.83 46.92
RxSight $134.48M 2.24 -$38.94M -$0.95 N/A
: In the previous week, iRadimed had 18 more articles in the media than RxSight. MarketBeat recorded 21 mentions for iRadimed and 3 mentions for RxSight. iRadimed's average media sentiment score of 0.64 beat RxSight's score of 0.00 indicating that iRadimed is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iRadimed
7 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
RxSight
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: iRadimed presently has a consensus target price of $120.00, indicating a potential upside of 39.76%. RxSight has a consensus target price of $9.78, indicating a potential upside of 34.68%. Given iRadimed's stronger consensus rating and higher possible upside, analysts plainly believe iRadimed is more favorable than RxSight.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRadimed
0 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
3.00
RxSight
3 Sell rating(s)

10 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
1.93
: iRadimed has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
: iRadimed has a net margin of 27.36% compared to RxSight's net margin of -28.96%. iRadimed's return on equity of 24.66% beat RxSight's return on equity.
Company Net Margins Return on Equity Return on Assets
iRadimed 27.36% 24.66% 21.47%
RxSight -28.96% -14.05% -12.54%
: 92.3% of iRadimed shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 36.8% of iRadimed shares are held by insiders. Comparatively, 9.6% of RxSight shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$86.28M	12.72	$22.48M	$1.83	46.92
RxSight	$134.48M	2.24	-$38.94M	-$0.95	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	27.36%	24.66%	21.47%
RxSight	-28.96%	-14.05%	-12.54%

Summary

iRadimed beats RxSight on 15 of the 17 factors compared between the two stocks.

How does RxSight compare to CONMED?

RxSight (NASDAQ:RXST) and CONMED (NYSE:CNMD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

: 78.8% of RxSight shares are owned by institutional investors. 9.6% of RxSight shares are owned by insiders. Comparatively, 0.3% of CONMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: RxSight currently has a consensus target price of $9.78, indicating a potential upside of 34.68%. CONMED has a consensus target price of $46.20, indicating a potential upside of 26.21%. Given RxSight's stronger consensus rating and higher possible upside, research analysts plainly believe RxSight is more favorable than CONMED.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RxSight
3 Sell rating(s)
10 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
1.93
CONMED
1 Sell rating(s)

6 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.86
: CONMED has a net margin of 4.00% compared to RxSight's net margin of -28.96%. CONMED's return on equity of 13.84% beat RxSight's return on equity.
Company Net Margins Return on Equity Return on Assets
RxSight -28.96% -14.05% -12.54%
CONMED 4.00% 13.84% 6.05%
: CONMED has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RxSight $134.48M 2.24 -$38.94M -$0.95 N/A
CONMED $1.37B 0.81 $47.06M $1.77 20.68
: RxSight has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, CONMED has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.
: In the previous week, CONMED had 20 more articles in the media than RxSight. MarketBeat recorded 23 mentions for CONMED and 3 mentions for RxSight. CONMED's average media sentiment score of 0.28 beat RxSight's score of 0.00 indicating that CONMED is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
RxSight
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
CONMED
1 Very Positive mention(s)
9 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
CONMED	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-28.96%	-14.05%	-12.54%
CONMED	4.00%	13.84%	6.05%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	2.24	-$38.94M	-$0.95	N/A
CONMED	$1.37B	0.81	$47.06M	$1.77	20.68

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CONMED	1 Very Positive mention(s)	9 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

CONMED beats RxSight on 9 of the 16 factors compared between the two stocks.

How does RxSight compare to BioLife Solutions?

RxSight (NASDAQ:RXST) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

: In the previous week, RxSight had 2 more articles in the media than BioLife Solutions. MarketBeat recorded 3 mentions for RxSight and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.34 beat RxSight's score of 0.00 indicating that BioLife Solutions is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
RxSight
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioLife Solutions
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: RxSight currently has a consensus target price of $9.78, indicating a potential upside of 34.68%. BioLife Solutions has a consensus target price of $32.00, indicating a potential upside of 48.49%. Given BioLife Solutions' stronger consensus rating and higher possible upside, analysts plainly believe BioLife Solutions is more favorable than RxSight.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RxSight
3 Sell rating(s)
10 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
1.93
BioLife Solutions
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.80
: 78.8% of RxSight shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 9.6% of RxSight shares are owned by insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: RxSight has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500.
: BioLife Solutions has a net margin of -4.50% compared to RxSight's net margin of -28.96%. BioLife Solutions' return on equity of 1.71% beat RxSight's return on equity.
Company Net Margins Return on Equity Return on Assets
RxSight -28.96% -14.05% -12.54%
BioLife Solutions -4.50% 1.71% 1.54%
: BioLife Solutions has lower revenue, but higher earnings than RxSight. BioLife Solutions is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RxSight $134.48M 2.24 -$38.94M -$0.95 N/A
BioLife Solutions $96.21M 10.95 -$4.59M -$0.11 N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioLife Solutions	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
BioLife Solutions	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-28.96%	-14.05%	-12.54%
BioLife Solutions	-4.50%	1.71%	1.54%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	2.24	-$38.94M	-$0.95	N/A
BioLife Solutions	$96.21M	10.95	-$4.59M	-$0.11	N/A

Summary

BioLife Solutions beats RxSight on 13 of the 17 factors compared between the two stocks.

How does RxSight compare to InMode?

RxSight (NASDAQ:RXST) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

: RxSight has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, InMode has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500.
: RxSight currently has a consensus target price of $9.78, indicating a potential upside of 34.68%. InMode has a consensus target price of $17.25, indicating a potential upside of 19.79%. Given RxSight's higher probable upside, analysts plainly believe RxSight is more favorable than InMode.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RxSight
3 Sell rating(s)
10 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
1.93
InMode
1 Sell rating(s)

5 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: InMode has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RxSight $134.48M 2.24 -$38.94M -$0.95 N/A
InMode $370.49M 2.46 $93.83M $1.44 10.00
: InMode has a net margin of 25.33% compared to RxSight's net margin of -28.96%. InMode's return on equity of 14.52% beat RxSight's return on equity.
Company Net Margins Return on Equity Return on Assets
RxSight -28.96% -14.05% -12.54%
InMode 25.33% 14.52% 12.88%
: 78.8% of RxSight shares are owned by institutional investors. Comparatively, 68.0% of InMode shares are owned by institutional investors. 9.6% of RxSight shares are owned by company insiders. Comparatively, 6.9% of InMode shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: In the previous week, RxSight had 2 more articles in the media than InMode. MarketBeat recorded 3 mentions for RxSight and 1 mentions for InMode. RxSight's average media sentiment score of 0.00 equaled InMode'saverage media sentiment score.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
RxSight
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
InMode
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
InMode	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$134.48M	2.24	-$38.94M	-$0.95	N/A
InMode	$370.49M	2.46	$93.83M	$1.44	10.00

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-28.96%	-14.05%	-12.54%
InMode	25.33%	14.52%	12.88%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InMode	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

InMode beats RxSight on 10 of the 15 factors compared between the two stocks.

Get RxSight News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXST vs. The Competition

Export

Metric	RxSight	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$300.56M	$7.14B	$6.25B	$11.87B
Dividend Yield	N/A	1.75%	2.73%	5.21%
P/E Ratio	-7.64	29.60	29.04	28.47
Price / Sales	2.24	55.86	476.61	60.94
Price / Cash	N/A	24.91	27.62	36.52
Price / Book	1.08	7.18	9.67	6.67
Net Income	-$38.94M	$158.34M	$3.55B	$332.53M
7 Day Performance	1.26%	2.64%	1.70%	2.01%
1 Month Performance	9.34%	4.99%	5.62%	9.20%
1 Year Performance	-50.41%	-3.14%	34.42%	39.59%

RxSight Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXST RxSight	1.5643 of 5 stars	$7.26 -1.6%	$9.78 +34.7%	N/A	$300.56M	$134.48M	N/A	220	Upcoming Earnings
AVNS Avanos Medical	1.0918 of 5 stars	$24.64 +0.1%	N/A	N/A	$1.15B	$701.20M	N/A	2,287	News Coverage Earnings Report
IRMD iRadimed	3.9737 of 5 stars	$88.62 -0.1%	$120.00 +35.4%	N/A	$1.13B	$83.81M	50.70	110	Earnings Report Dividend Announcement
CNMD CONMED	3.1949 of 5 stars	$37.57 -2.0%	$49.20 +31.0%	N/A	$1.13B	$1.37B	24.88	3,900	Earnings Report Analyst Downgrade
BLFS BioLife Solutions	2.9714 of 5 stars	$21.13 -1.3%	$32.00 +51.5%	N/A	$1.02B	$96.21M	N/A	440	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXST) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RxSight (RXST) Competitors

RXST vs. AVNS, IRMD, CNMD, BLFS, and INMD

How does RxSight compare to Avanos Medical?

Summary

How does RxSight compare to iRadimed?

Summary

How does RxSight compare to CONMED?

Summary

How does RxSight compare to BioLife Solutions?

Summary

How does RxSight compare to InMode?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST vs. The Competition

RxSight Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RxSight (RXST) Competitors

RXST vs. AVNS, IRMD, CNMD, BLFS, and INMD

How does RxSight compare to Avanos Medical?

Summary

How does RxSight compare to iRadimed?

Summary

How does RxSight compare to CONMED?

Summary

How does RxSight compare to BioLife Solutions?

Summary

How does RxSight compare to InMode?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXST vs. The Competition

RxSight Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools